UK MHRA approves Marksans All in One oral solution

Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs

The UK MHRA has granted market authorisation to Marksans Pharma’s wholly owned subsidiary Bell Sons & Co. for Bells Healthcare All in One oral solution. The company stated in a regulatory filing

Each 20 ml dose contains Paracetamol Ph. Eur. 500.0 mg, Guaifenesin Ph. Eur. 200.0 mg and Phenylephrine Hydrochloride Ph. Eur. 10.0 mg.

Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs.
This is the first generic approval by UK MHRA for the product.

Marksans will manufacture the products at its UK MHRA approved facility Bell Sons & Co. (Druggists) in UK.